The U.S. Food and Drug Administration has accepted Cogent Biosciences’ New Drug Application for bezuclastinib in patients with non‑advanced systemic mastocytosis, setting a Prescription Drug User Fee Act target action date of December 30 2026. The acceptance signals that the agency sees no major review issues and will not convene an advisory committee, indicating a streamlined review path for the indication.
Bezuclastinib is a selective, oral KIT D816V inhibitor that demonstrated a 8.91‑point placebo‑adjusted improvement in total symptom score (p = 0.0002) and a 87.4% rate of ≥50% serum tryptase reduction versus 0% on placebo in the SUMMIT Part 2 trial. The data confirm the drug’s ability to relieve symptoms and reduce disease biomarkers in a rare patient population that currently has limited targeted options.
The approval would position bezuclastinib as a best‑in‑class therapy for non‑advanced systemic mastocytosis, a niche that is currently served only by symptomatic treatments and the advanced‑SM drug avapritinib (Ayvakit). By targeting the same KIT D816V mutation but in a broader, less aggressive disease subset, bezuclastinib could capture a sizable share of the unmet‑needs market and strengthen Cogent’s competitive moat.
Cogent’s financial runway is reinforced by a $475 million equity and convertible‑note offering completed in November 2025, giving the company ample capital to support launch preparations. The company also plans to submit NDAs for bezuclastinib in gastrointestinal stromal tumors and advanced systemic mastocytosis in 2026, expanding the drug’s potential market beyond the non‑advanced indication.
The FDA acceptance is a key regulatory milestone that could accelerate the company’s path to commercialization, enhance its pipeline profile, and provide a new revenue source for a rare‑disease portfolio. Investors will view the event as a positive development that strengthens Cogent’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.